echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > South Africa accuses big pharmaceutical companies of plotting "evil plots"

    South Africa accuses big pharmaceutical companies of plotting "evil plots"

    • Last Update: 2014-01-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    - the leaked documents show that large pharmaceutical companies oppose the patent law amendment movement source: China Council for the promotion of drugs 2014-01-21 the pharmaceutical industry was accused of many illegal acts, but not often accused of "Satan plot" that would lead to "ethnic extinction" It was Aaron Motsoaledi, South Africa's health minister, who slammed large pharmaceutical companies in Friday's report for funding a public relations campaign aimed at opposing the favorable generic terms of the new patent law According to documents leaked by Reuters, ipasa is considering providing us $600000 organization to oppose the new patent law to tighten the country's "evergreen" provision of patents for minor changes in drugs Ipasa members include Sanofi, Baite international, Pfizer and Novartis The South African government wants more generic drugs on the market to reduce national health care costs These changes also benefit domestic pharmaceutical companies such as Aspen pharmaceuticals and Adcock Ingram Health care advocates in South Africa claim that so far the government has not even scrutinized patent applications This has resulted in many patents for the same drug, and hindered the development of the generic industry in the direction of making more affordable drugs Reuters reported that the event, planned by the US public affairs consulting company, recommended that ipasa strive to postpone the determination of the new patent law until after the general election in May The plan is to persuade lawmakers to vote for a change in patent law with serious political consequences Val Beaumont, a spokeswoman for ipasa, admitted to the press that the document was authentic, but it was just a proposal that ipasa had not yet approved "This proposal has not been accepted or implemented," she told Reuters As other countries strive to reduce medical costs, large pharmaceutical companies have been fighting intellectual property around the world, especially in India and China China, for example, last year cancelled a patent on Gilead Sciences' HIV and hepatitis B drug, Viread (tenofovir), when a generic company challenged it The move is expected to halve the price of the drug Such moves have scared pharmaceutical companies of patent law changes South Africa is a small market, but it is one of the emerging markets that pharmaceutical companies are turning to after the slowdown in developed countries Now that the document has been released, Reuters pointed out that the industry association is likely to terminate the plan Motsoaledi confessed his thoughts on the sport "This document will sentence many South Africans to death," he said It's a genocide plan " Original link: http:// UTM \ \
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.